Jacob A. Frenkel Buys 200,000 Shares of Common Stock

On February 26, 2026, Jacob A. Frenkel, a director at BRAINSTORM CELL THERAPEUTICS INC. (BCLI), acquired 200,000 shares of common stock through the award of restricted stock units (RSUs). These RSUs were granted under the company's 2014 Global Share Option Plan. The award vests such that 50% vests immediately on the grant date, and the remaining 50% vests on the six-month anniversary of the grant date, contingent upon continued employment with the Issuer. The acquisition was made at a price of $0.00 per share, indicating it was a grant rather than a purchase. Following this transaction, Mr. Frenkel owns 243,777 shares of common stock.